# Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)

Source: https://onco.cc/trials/nct06225596/  
OnCo record `nct06225596` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Zelenectide pevedotin, Pembrolizumab, Carboplatin, Cisplatin, Gemcitabine and Gemcitabine + cisplatin in bladder & urothelial cancer, run by BicycleTx Limited, active and no longer recruiting.

## Summary

Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) is a phase 2 interventional study registered as NCT06225596 by BicycleTx Limited, with 375 participants enrolled, started 2024-01-24 and due to reach its primary completion in 2028-03. Interventions recorded: Zelenectide pevedotin, Pembrolizumab, Gemcitabine + cisplatin Or carboplatin and Avelumab.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06225596
- Phase: 2
- Setting: A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
- Sponsor: BicycleTx Limited
- Enrolled: 375

## Sources

- ClinicalTrials.gov NCT06225596: https://clinicaltrials.gov/study/NCT06225596

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Gemcitabine + cisplatin](https://onco.cc/drugs/gemcitabine-cisplatin/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Zelenectide pevedotin](https://onco.cc/drugs/zelenectide-pevedotin/)

---
JSON: https://onco.cc/api/v1/entities/nct06225596.json